Reorganization of prion protein membrane environment during low potassium-induced apoptosis in primary rat cerebellar neurons.
We studied the changes occurring in the membrane environment of prion protein (PrP) during apoptosis induced by low potassium in primary rat cerebellar neurons. Ceramide levels increased during apoptosis-inducing treatment, being doubled with respect to time-matched controls after 24 h. Sphingomyelin levels were parallely decreased, while cholesterol and ganglioside contents were not affected. Changes in ceramide and sphingomyelin composition were exclusively restricted to a detergent-resistant membrane fraction. The pro-apoptotic treatment was accompanied by the down-regulation of PrP and of the non-receptor kinase Fyn. The levels of PrP and Fyn were correspondingly reduced in the detergent-resistant membrane fraction. In control cells, the membrane microenvironment separated by immunoprecipitation with anti-PrP antibody contained 80% of the detergent-resistant PrP and 35% and 38% of the sphingolipids and cholesterol respectively. Upon low potassium treatment, 20% of the PrP originally present in the detergent-resistant fraction was immunoprecipitated, together with 19% of sphingolipids and 22% of cholesterol. Thus, PrP in the immunoprecipitate from apoptotic cells was ninefold less than in control ones, while sphingolipids and cholesterol were about 50% with respect to controls cells. The molar ratio between cholesterol, sphingomyelin and ceramide was 15 : 6 : 1 in the PrP-rich environment from control neurons, and 6 : 2 : 1 in that from apoptotic cells.
Rivaroli
Anna
A
Center of Excellence on Neurodegenerative Diseases, Study Center for the Biochemistry and Biotechnology of Glycolipids, Department of Medical Chemistry, Biochemistry and Biotechnology, University of Milan, Milan, Italy.
Prioni
Simona
S
Loberto
Nicoletta
N
Bettiga
Arianna
A
Chigorno
Vanna
V
Prinetti
Alessandro
A
Sonnino
Sandro
S
D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000187:drug effects*; D002478:Cells, Cultured; D002531:Cerebellum / Q000166:cytology*; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D053938:DNA Fragmentation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D047468:Immunoprecipitation / Q000379:methods; D050356:Lipid Metabolism / Q000187:drug effects; D008715:Methionine / Q000378:metabolism; D009474:Neurons / Q000187:drug effects*; D011188:Potassium / Q000494:pharmacology*; D011328:Prions / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013110:Sphingosine / Q000493:pharmacokinetics; D014316:Tritium / Q000493:pharmacokinetics
D011328:Prions; D014316:Tritium; D008715:Methionine; D013110:Sphingosine; D011188:Potassium